
    
      all the participants enrolled in the study will be randomly assigned in a 1:1 ratio, the
      experimental group will receive leflunomide + low dose glucocorticoids therapy on the basis
      of conservative treatment, while the control group receive conservative treatment only.
      Conservative treatment is defined as the treatment of delaying the progress of renal
      function, including low-protein diet supplemented with ketoacid therapy, Renin Angiotensin
      system (RAS) inhibitor, blood pressure control, lipid-regulating therapy and antiplatelet
      aggregation therapy. The course of treatment will last one year, then the
      leflunomide+glucocorticoids group will continue the conservative treatment. Participants will
      be follow-up at least 98 weeks.
    
  